The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease
-
Abstract
Background: The ratio of low- to high-density lipoprotein-cholesterol (LDL-C/HDL-C) conventionally represents the balance of proatherogenic and anti-atherogenic lipids. However, growing evidence supports the idea that the ratio of apolipoprotein (apo) B/apoAI is a better index for risk assessment of coronary artery disease (CAD). The aim of this study was to evaluate the efficiency of advanced profile of serum (apo)lipoproteins for predicting stable CAD in secondary prevention.
Methods: The study subjects, 138 men and 126 women aged 40–70years, were classified as CAD cases or controls, according to the results of coronary angiography. The severity of CAD was scored on the basis of the number and extent of lesions in coronary arteries. Serum (apo)lipoproteins were measured by immunoturbidometric and electrophoresis methods.
Results: Patients with CAD compared with controls had increased serum levels of triglycerides (2.6±2.0 vs. 2.0±1.2mmol/L, p≤0.005), apoB (1.36±0.31 vs. 1.19±0.24g/L, p≤0.0001), lipoprotein(a) [Lp(a)] (0.69±0.60 vs. 0.43±0.31g/L, p≤0.0001) and apoB/apoAI ratio (1.07±0.32 vs. 0.87±0.18, p≤0.0001), and decreased serum levels of HDL-C (1.02±0.29 vs. 1.11±0.34mmol/L, p≤0.03), apoAI (1.32±0.22 vs. 1.37±0.19g/L, p≤0.04) and LDL-C/apoB ratio (0.91±0.32 vs. 1.02±0.25 mmol/g, p≤0.01). Multiple logistic regression analysis after adjusting for major risk factors showed that the apoB/apoAI ratio, apoB and Lp(a) were among seven significant and independent determinants of CAD. The area under the receiver operating characteristic (ROC) curves (AUC) as a relative measure of test efficiency was highest and significant for the apoB/apoAI ratio (AUC=0.71, p≤0.0001), apoB (0.67, p≤0.0001), Lp(a) (0.63, p≤0.001), the LDL-C/apoB ratio (0.62, p≤0.006), triglycerides (0.62, p≤0.004) and apoAI (0.58, p≤0.05). ANOVA analysis showed significant association for the apoB/apoAI ratio, apoB, Lp(a) and triglycerides, and moderate association for total cholesterol and its subfractions, with the severity of CAD.
Conclusions: The results indicate that the apoB/apoAI ratio, apoB and Lp(a) are independent risk factors for CAD and are superior to any of the cholesterol ratios. We suggest using the apoB/apoAI ratio as the best marker of CAD in clinical practice.
Clin Chem Lab Med 2006;44:1015–21.
References
1. Parmley WW. Nonlipoprotein risk factors for coronary heart disease: evaluation and management. Am J Med 1997; 102:7–14.10.1016/S0002-9343(97)00461-0Suche in Google Scholar
2. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34:1348–59.10.1016/S0735-1097(99)00387-3Suche in Google Scholar
3. Elisaf MS, Siamopoulos KC, Tselegarides TJ, Bairaktari ET, Goudevenos JA, Tselepis AD, et al. Lipid abnormalities in Greek patients with coronary artery disease. Int J Cardiol 1997; 59:177–84.10.1016/S0167-5273(96)02916-6Suche in Google Scholar
4. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990; 150:1629–33.10.1001/archinte.1990.00040031629009Suche in Google Scholar
5. Ramachandran A, Satyamurthy I, Snehalatha C, Satyavani K, Sivansankari S, Misra J, et al. Risk variables for coronary artery disease in Asian Indian. Am J Cardiol 2001; 87:267–71.10.1016/S0002-9149(00)01356-4Suche in Google Scholar
6. Haidari M, Moghadam M, Chinicar M, Ahmadieh A, Doosti M. Apolipoprotein B is the best predictor of coronary artery disease in Iranian normolipidemic patients. Clin Biochem 2001; 34:149–55.10.1016/S0009-9120(01)00192-8Suche in Google Scholar
7. Rahmani M, Raiszadeh F, Allahverdian S, Kiaii S, Navab M, Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002; 162:381–9.10.1016/S0021-9150(01)00715-8Suche in Google Scholar
8. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937–52.10.1016/S0140-6736(04)17018-9Suche in Google Scholar
9. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006; 259:259–66.10.1111/j.1365-2796.2005.01610.xSuche in Google Scholar PubMed
10. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42:1355–63.10.1515/CCLM.2004.254Suche in Google Scholar PubMed
11. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapmen MJ, Couture P, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259:247–58.10.1111/j.1365-2796.2006.01616.xSuche in Google Scholar
12. Rodriguez CR, Seman LJ, Ordovas JM, Jenner J, Genest MJ, Wilson PW, et al. Lipoprotein(a) and coronary heart disease. Chem Phys Lipids 1994; 67/68:389–98.10.1016/0009-3084(94)90161-9Suche in Google Scholar
13. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82:57–66U.10.1016/S0002-9149(98)00954-0Suche in Google Scholar
14. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis 2002; 163:377–84.10.1016/S0021-9150(02)00026-6Suche in Google Scholar
15. Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000; 153:445–51.10.1016/S0021-9150(00)00427-5Suche in Google Scholar
16. Cantin B, Després JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men: the Quebec Cardiovascular Study. Am J Cardiol 2002; 89:662–6.10.1016/S0002-9149(01)02336-0Suche in Google Scholar
17. Wang W, Hu D, Lee ET, Fabsitz RR, Welty TK, Robbins DC, et al. Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease: the Strong Heart Study. Ann Epidemiol 2002; 12:107–14.10.1016/S1047-2797(01)00273-3Suche in Google Scholar
18. Sunayama S, Daida H, Mokuno H, Mokuno H, Miyano H, Yokoi H, et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women <55 years of age. Circulation 1996; 94:1263–8.10.1161/01.CIR.94.6.1263Suche in Google Scholar
19. Sirnons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo Study. Atherosclerosis 1993; 99:87–95.10.1016/0021-9150(93)90054-XSuche in Google Scholar
20. Rasouli M, Kiasari AM. Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic lipids and (apo)lipoproteins. Clin Chem Lab Med 2006; 44:43–50.10.1515/CCLM.2006.009Suche in Google Scholar PubMed
21. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87:1411–4.10.1016/S0002-9149(01)01566-1Suche in Google Scholar
22. Korhonen T, Sovolainen MJ, Koistinen J, Ikaheimo M, Linnaluoto MK, Kervinen K, et al. Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 1996 127:213–20.10.1016/S0021-9150(96)05958-8Suche in Google Scholar
23. Graille V, Ferrieres J, Evans A, Amouyel P, Arveiler D, Luc G, et al. Associations between classical cardiovascular risk factors and coronary artery disease in two countries: the PRIME study. Intern J Cardiol 2000; 74:191–8.10.1016/S0167-5273(00)00283-7Suche in Google Scholar
24. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86:943–9.10.1016/S0002-9149(00)01127-9Suche in Google Scholar
25. Gotto AM. Triglyceride as a risk factor for coronary heart disease. Am J Cardiol 1998; 82:22–250.10.1016/S0002-9149(98)00770-XSuche in Google Scholar
26. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level. A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213–9.10.1097/00043798-199604000-00014Suche in Google Scholar
27. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease – an eight-year follow up in the Copenhagen Male study. Circulation 1998; 97:1029–36.10.1161/01.CIR.97.11.1029Suche in Google Scholar
28. Meraji S, Abuja PM, Hayn M, Kostner GM, Morris R, Oraii S, et al. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran. Atherosclerosis 2000; 150:403–12.10.1016/S0021-9150(99)00394-9Suche in Google Scholar
29. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia and the metabolic syndrome. Am J Cardiol 1998; 81:18–25B.10.1016/S0002-9149(98)00033-2Suche in Google Scholar
30. Sacks FM. Why cholesterol as a central theme in coronary artery disease? Am J Cardiol 1998; 82:14–7T.10.1016/S0002-9149(98)00717-6Suche in Google Scholar
31. Ciardullo AV, Azzolini L, Bevini M, Cadioli T, Malavasi P, Morellini A, et al. Non-HDL cholesterol predicts coronary heart disease in primary prevention: findings from an Italian 40–69-year-old cohort in general practice. Monaldi Arch Chest Dis 2004; 62:69–72.10.4081/monaldi.2004.672Suche in Google Scholar
32. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Inter J Cardiol 2000; 74:S17–22.10.1016/S0167-5273(99)00107-2Suche in Google Scholar
33. Gardner CD, Fortmann SP, Krauss RM. Association of small low density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 1996; 276:875–81.10.1001/jama.1996.03540110029028Suche in Google Scholar
34. Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J 2002; 144:1026–35.10.1067/mhj.2002.126119Suche in Google Scholar
35. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins AI and B, and HDL subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001; 104:1108–16.10.1161/hc3501.095214Suche in Google Scholar
36. Tasaki H, Nakashima Y, Nandate H, Yashiro A, Kawashima T, Kuroiwa A. Comparison of serum lipid values in variant angina pectoris and fixed coronary artery disease with normal subjects. Am J Cardiol 1989; 63:1441–5.10.1016/0002-9149(89)90004-0Suche in Google Scholar
37. Orth-Gomer K, Mittleman M, Schenck-Gustagsson K, Eriksson M, Belkic K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95:329–34.10.1161/01.CIR.95.2.329Suche in Google Scholar PubMed
38. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas AM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994; 90:1688–95.10.1161/01.CIR.90.4.1688Suche in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Laboratory medicine in the 2000s: programmed death or rebirth?
- Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events
- Haptoglobin polymorphism in patients with preeclampsia
- Fifteen polymorphisms in endothelin-1, endothelin-2 and endothelin-receptor-A genotyped by four duplex assays and seven simple assays on a LightCycler using hybridization probes
- Optimization of an enzymatic method for the determination of lysosomal N-acetyl-β-D-hexosaminidase and β-glucuronidase in synovial fluid
- An improved laboratory protocol to assess subarachnoid haemorrhage in patients with negative cranial CT scan
- Association of aminothiols with the clinical outcome in hemodialysis patients: comparison of chromatography and immunoassay for homocysteine determination
- Poor prognosis indicated by nucleated red blood cells in peripheral blood is not associated with organ failure of the liver or kidney
- Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium
- Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis
- Relationship between serum uric acid, creatinine, albumin and gestational diabetes mellitus
- Aminothiols in human brain tumors
- Measurement of carnitine in hemodialysis patients – adaptation of an enzymatic photometric method for an automatic analyzer
- A robust liquid chromatography tandem mass spectrometry method for total plasma homocysteine determination in clinical practice
- Establishment of reference distributions and decision values for thyroid antibodies against thyroid peroxidase (TPOAb), thyroglobulin (TgAb) and the thyrotropin receptor (TRAb)
- Effects of a long-distance run on cardiac markers in healthy athletes
- α-Tocopherol supplementation reduces the elevated 8-hydroxy-2-deoxyguanosine blood levels induced by training in basketball players
- Influence of the needle bore size used for collecting venous blood samples on routine clinical chemistry testing
- The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease
- Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system
- Preliminary performance evaluation of blood gas analyzers
- A cost-effectiveness evaluation of reticulocyte measurement in new outpatients with or without hematologic disorders
- Guidelines for setting up an External Quality Assessment Scheme for blood smear interpretation. Part II: survey preparation, statistical evaluation and reporting
- Free light chain testing in follow-up of multiple myeloma
- Blood reactive oxygen metabolites (ROMs) and total antioxidant status (TAS) in patients with laryngeal squamous cell carcinoma after surgical treatment
- SIBioC 2006 38th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, Turin, Italy, September 19–22, 2006
- Third Santorini Biologie Prospective Conference 2006: From Human Genetic Variations to Prediction of Risks and Responses to Drugs and the Environment, Santorini Island, Greece, September 29 - October 2, 2006
Artikel in diesem Heft
- Laboratory medicine in the 2000s: programmed death or rebirth?
- Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events
- Haptoglobin polymorphism in patients with preeclampsia
- Fifteen polymorphisms in endothelin-1, endothelin-2 and endothelin-receptor-A genotyped by four duplex assays and seven simple assays on a LightCycler using hybridization probes
- Optimization of an enzymatic method for the determination of lysosomal N-acetyl-β-D-hexosaminidase and β-glucuronidase in synovial fluid
- An improved laboratory protocol to assess subarachnoid haemorrhage in patients with negative cranial CT scan
- Association of aminothiols with the clinical outcome in hemodialysis patients: comparison of chromatography and immunoassay for homocysteine determination
- Poor prognosis indicated by nucleated red blood cells in peripheral blood is not associated with organ failure of the liver or kidney
- Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium
- Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis
- Relationship between serum uric acid, creatinine, albumin and gestational diabetes mellitus
- Aminothiols in human brain tumors
- Measurement of carnitine in hemodialysis patients – adaptation of an enzymatic photometric method for an automatic analyzer
- A robust liquid chromatography tandem mass spectrometry method for total plasma homocysteine determination in clinical practice
- Establishment of reference distributions and decision values for thyroid antibodies against thyroid peroxidase (TPOAb), thyroglobulin (TgAb) and the thyrotropin receptor (TRAb)
- Effects of a long-distance run on cardiac markers in healthy athletes
- α-Tocopherol supplementation reduces the elevated 8-hydroxy-2-deoxyguanosine blood levels induced by training in basketball players
- Influence of the needle bore size used for collecting venous blood samples on routine clinical chemistry testing
- The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease
- Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system
- Preliminary performance evaluation of blood gas analyzers
- A cost-effectiveness evaluation of reticulocyte measurement in new outpatients with or without hematologic disorders
- Guidelines for setting up an External Quality Assessment Scheme for blood smear interpretation. Part II: survey preparation, statistical evaluation and reporting
- Free light chain testing in follow-up of multiple myeloma
- Blood reactive oxygen metabolites (ROMs) and total antioxidant status (TAS) in patients with laryngeal squamous cell carcinoma after surgical treatment
- SIBioC 2006 38th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, Turin, Italy, September 19–22, 2006
- Third Santorini Biologie Prospective Conference 2006: From Human Genetic Variations to Prediction of Risks and Responses to Drugs and the Environment, Santorini Island, Greece, September 29 - October 2, 2006
